Literature DB >> 20220135

The annexin I sequence gln(9)-ala(10)-trp(11)-phe(12) is a core structure for interaction with the formyl peptide receptor 1.

Charlotta Movitz1, Lars Brive, Kristoffer Hellstrand, Marie-Josèphe Rabiet, Claes Dahlgren.   

Abstract

The N-terminal part of the calcium-regulated and phospholipid-binding protein annexin AI contains peptide sequences with pro- and anti-inflammatory activities. We have earlier shown that a proinflammatory signal triggered by one of these peptides, Gln(9)-Lys(25), is mediated by FPR1, a member of the formyl peptide receptor family expressed in human neutrophils. To determine the core structure in Gln(9)-Lys(25), smaller peptides were generated, and their capacity to activate neutrophils was determined. A peptide spanning from amino acid Glu(14) to Lys(25) was inactive, whereas the activity was retained in the Gln(9)-Tyr(20) peptide. Removal of amino acids from the C and N terminus of Gln(9)-Tyr(20) revealed that the first amino acid (Gln(9)) was of the utmost importance for activity. The core structure that activated the neutrophil NADPH oxidase to release superoxide anions was Gln(9)-Ala(10)-Trp(11)-Phe(12). This peptide also inhibited the activity induced by N-formyl-Met-Leu-Phe and WKYMVM. A structural model of the peptide agonist-FPR1 complex suggests that the transmembrane part of the binding pocket of the receptor binds optimally to a tetrapeptide. According to the model and the results presented, the N-terminal amino acid glutamine in Gln(9)-Phe(12) is located close to the bottom of the binding cleft, leaving for steric reasons insufficient space to extend the peptide at the N terminus. The addition of amino acids at the C terminus will not affect binding. The model presented may be helpful in developing specific FPR1 ligands.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220135      PMCID: PMC2863206          DOI: 10.1074/jbc.M109.080465

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure.

Authors:  Tetsuji Okada; Minoru Sugihara; Ana-Nicoleta Bondar; Marcus Elstner; Peter Entel; Volker Buss
Journal:  J Mol Biol       Date:  2004-09-10       Impact factor: 5.469

2.  Fluorescence analysis of the size of a binding pocket of a peptide receptor at natural abundance.

Authors:  L A Sklar; S P Fay; B E Seligmann; R J Freer; N Muthukumaraswamy; H Mueller
Journal:  Biochemistry       Date:  1990-01-16       Impact factor: 3.162

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Crystal structure of human annexin I at 2.5 A resolution.

Authors:  X Weng; H Luecke; I S Song; D S Kang; S H Kim; R Huber
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

5.  Formyl peptide receptor chimeras define domains involved in ligand binding.

Authors:  H D Perez; R Holmes; L R Vilander; R R Adams; W Manzana; D Jolley; W H Andrews
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

7.  The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.

Authors:  Huamei Fu; Johan Bylund; Anna Karlsson; Sara Pellmé; Claes Dahlgren
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

8.  An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family.

Authors:  Stefanie Ernst; Carsten Lange; Andreas Wilbers; Verena Goebeler; Volker Gerke; Ursula Rescher
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

9.  Aromatic residues at the extracellular ends of transmembrane domains 5 and 6 promote ligand activation of the G protein-coupled alpha-factor receptor.

Authors:  Jennifer C Lin; William Parrish; Markus Eilers; Steven O Smith; James B Konopka
Journal:  Biochemistry       Date:  2003-01-21       Impact factor: 3.162

10.  Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.

Authors:  Yoe-Sik Bae; Ha Young Lee; Eun Jin Jo; Jung Im Kim; Hyun-Kyu Kang; Richard D Ye; Jong-Young Kwak; Sung Ho Ryu
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

View more
  15 in total

1.  Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Liliya N Kirpotina; Lars Brive; Claes Dahlgren; Mark A Jutila; Mark T Quinn
Journal:  J Mol Model       Date:  2011-11-30       Impact factor: 1.810

2.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

3.  4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Authors:  Liliya N Kirpotina; Igor A Schepetkin; Andrei I Khlebnikov; Olga I Ruban; Yunjun Ge; Richard D Ye; Douglas J Kominsky; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2017-07-08       Impact factor: 5.858

4.  Receptor-dependent and -independent immunomodulatory effects of phenol-soluble modulin peptides from Staphylococcus aureus on human neutrophils are abrogated through peptide inactivation by reactive oxygen species.

Authors:  Huamei Forsman; Karin Christenson; Johan Bylund; Claes Dahlgren
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

Review 5.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

6.  Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2010-10-13       Impact factor: 4.436

7.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

8.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

Review 9.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

10.  The role of water in activation mechanism of human N-formyl peptide receptor 1 (FPR1) based on molecular dynamics simulations.

Authors:  Shuguang Yuan; Umesh Ghoshdastider; Bartosz Trzaskowski; Dorota Latek; Aleksander Debinski; Wojciech Pulawski; Rongliang Wu; Volker Gerke; Slawomir Filipek
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.